Literature DB >> 31139906

Accuracy of the preoperative PSA level for predicting clinically significant incidental transitional zone-prostate cancer before endoscopic enucleation of very large adenoma.

Vincent Misraï1, Marie Pasquie2, Benoit Bordier2, Julien Guillotreau2, Alexandre Gryn2, Julien Palasse3, Eric Bruguière4, Benjamin Pradere5, Morgan Rouprêt6, Kevin C Zorn7.   

Abstract

OBJECTIVE: To analyse the accuracy of high preoperative PSA levels for predicting transitional zone incidental PCa (TZ-PCa) in men with very large prostates.
MATERIALS AND METHODS: Perioperative data from 375 consecutive patients who underwent endoscopic enucleation of the prostate (EEP) for benign prostatic obstruction between July 2013 and December 2018 were retrospectively reviewed. Patients were stratified into three groups according to the preoperative PSA level: low-PSA (< 4 ng/mL), intermediate-PSA (4 ≤ PSA < 10 ng/mL) and high-PSA (≥ 10 ng/mL). Men in each group were propensity score matched by age, 5α-reductase inhibitor (5-ARI) use, prostate volume and mpMRI. The TZ-PCa incidence rate was retrospectively compared by preoperative PSA level in a propensity score model including all predetermined variables.
RESULTS: Age, prostate volume, 5-ARI use were similar between patient groups. The median PSA levels in the low-, intermediate- and high-PSA groups were 3 [2.3; 3.4], 6.6 [5.3; 8.1] and 12.7 [11; 16.7] ng/mL, respectively. The median prostate volume was > 100 grams in all groups (108, 105 and 120 cc, respectively). The T1a-Gleason 6 incidental TZ-PCa rate was statistically comparable between the three groups (3.4, 5.1 and 8.6% in the low-, intermediate- and high-PSA groups, respectively). The detection rate of clinically significant TZ-PCa was low for preoperative PSA levels > 4 ng/mL (1.7%); with no difference between the intermediate- and high-PSA groups.
CONCLUSION: In men with large glands, the clinically significant incidental TZ-PCa detection rate was similar regardless of the preoperative PSA level stratum. Such details may help with patient counselling during BPH surgical management.

Entities:  

Keywords:  Benign prostatic obstruction; PSA; Prostate; Prostate cancer

Year:  2019        PMID: 31139906     DOI: 10.1007/s00345-019-02823-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  3 in total

1.  Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia.

Authors:  Malek Meskawi; Pierre-Alain Hueber; Roger Valdivieso; Pierre I Karakiewicz; Benjamin Pradere; Vincent Misrai; Bilal Chughtai; Kevin C Zorn
Journal:  World J Urol       Date:  2018-11-26       Impact factor: 4.226

2.  Risk factors for incidental prostate cancer-who should not undergo vaporization of the prostate for benign prostate hyperplasia?

Authors:  Susan Voigt; Friederike Hüttig; Rainer Koch; Stefan Propping; Catharina Propping; Marc-Oliver Grimm; Manfred Wirth
Journal:  Prostate       Date:  2011-02-09       Impact factor: 4.104

Review 3.  EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction.

Authors:  Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas
Journal:  Eur Urol       Date:  2015-01-19       Impact factor: 20.096

  3 in total
  1 in total

1.  The significance of a high preoperative PSA level for the detection of incidental prostate cancer in LUTS patients with large prostates.

Authors:  Giuseppe Magistro; Patrick Keller; Thilo Westhofen; Melanie Schott; Alexander Tamalunas; Philipp Weinhold; Christian G Stief
Journal:  World J Urol       Date:  2020-06-25       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.